◆英語タイトル：Global Insulin Resistance Market - 2023-2030
	◆商品コード：DTM23FB16 ◆発行会社（リサーチ会社）：DataM Intelligence ◆発行日：2023年1月 ◆ページ数：200 ◆レポート形式：英語 / PDF ◆納品方法：Eメール ◆調査対象地域：グローバル ◆産業分野：医療

The Global Insulin Resistance Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 4.2% during the forecast period (2023-2030).

Insulin resistance is an abnormally slow physiologic reaction to normal insulin concentrations. When cells in the muscles, fat, and liver do not respond to insulin well and cannot utilize glucose from the blood for energy, this condition is known as insulin resistance. The pancreas produces more insulin as a result. Blood sugar levels rise over time. Type 2 diabetes, cholesterol, blood pressure, and obesity are just a few of the conditions that are a part of insulin resistance syndrome.

Market Dynamics

The major factors driving the global insulin resistance market are the growing sedentary lifestyle and expanding diabetes prevalence, the market will also be driven by reimbursement and other pricing-related government regulations, and the growing healthcare sector and increased public knowledge of cutting-edge medical procedures will propel the market.

Growing sedentary lifestyle and expanding diabetes prevalence.

The market for insulin resistance is expanding as a result of rising sedentary lifestyles and rising diabetes prevalence. Patients with insulin resistance are expected to increase due to an aging population, an increase in sedentary lifestyles, and an increase in obesity incidence. Concerns are increased by sedentary lifestyle adoption and a decline in physical activity. In the glucose tolerance test, blood samples are taken after glucose is administered to assess how rapidly it is eliminated from the body. Typically, the test is used to check for diabetes, insulin resistance, decreased beta cell activity, reactive hypoglycemia, acromegaly, and other less common abnormalities of carbohydrate metabolism.

According to International Diabetes Federation estimates that 537 million adults (20-79 years old) will have diabetes by 2021. By 2030, there will be 643 million people worldwide living with diabetes, and by 2045, there will be 783 million; 3 in 4 individuals with diabetes reside in low- and middle-income nations. Adults with diabetes make up almost one in two people (240 million). The market is driven by the rising prevalence of diabetes globally.

Limited pharmaceutical choices and lack of information on insulin resistance is expected to hamper the market’s growth.

The availability of few medications and the lack of knowledge about insulin resistance are some of the factors expected to hinder the growth of the insulin resistance market. Additionally, the industry needs more reimbursement in developing and rising nations.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. An increased risk of developing a serious disease from COVID-19 may exist in individuals with specific underlying medical disorders. Diabetes, cardiac issues, obesity, and chronic kidney disease are some ailments. According to a CDC specific study, type 2 diabetes patients had a higher risk of developing severe COVID-19-related illnesses, according to the CDC. Accessibility and affordability have increased in priority due to the COVID-19 pandemic, which also affected diabetic developer strategies.

To assist patients in getting insulin during the pandemic, numerous pharmaceutical companies operating in the US market have publicly publicized programs. When many diabetes patients may not have access to healthcare due to the socio-economic impact of the COVID-19 epidemic. Drug manufacturers have a greater chance to produce novel and more approachable therapies for the diabetic population due to the increased demand for insulin and anti-diabetics.

Segment Analysis

Concentrated insulin products of Insulin resistance the segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Over the past few years, there have been more concentrated insulin products available in the US to treat diabetic patients. These medications may give patients options to improve glycemic control with treatment regimens that may increase their adherence to therapy since they contain more units of insulin per milliliter than typical U-100 insulins. All concentrated insulins are offered in distinctive prefilled pen devices that make it easy to identify the product and administer doses precisely.

Recent developments in concentrated insulins (exceeding 100 units/mL) and specialized equipment have given persons with diabetes new treatment choices for basal and prandial insulin supplementation. The concentrations of concentrated insulin formulations range from 2-fold (insulin lispro 200 units/mL), which has a fast-acting prandial effect, to 5-fold (human regular insulin 500 units/mL), which has basal and short-acting prandial activities. Degludec 200 units/mL and glargine 300 units/mL are two long-acting basal insulins. Concentrated insulins were created with the intention of simplifying the administration of insulin by lowering the volume and frequency of injections and, in certain cases, by utilizing modified pharmacokinetic and pharmacodynamic features. The market is driven by the development of the product and its use.

Geographical Analysis

North America holds the largest market share in the global Insulin resistance market.

Nearly 40% of young adults without diabetes, according to research from the University of Alabama at Birmingham in 2021, have insulin resistance, a disease in which the body does not respond to insulin as it should and cannot use blood glucose for energy. In the United States, where nearly 50% of the earnings for the manufacturers of insulin come from within the nation, the cost aspect is the biggest concern.

Under the direction of the Institute of Nutrition, Metabolism, and Diabetes, the Canadian Institutes of Health Research is funding cutting-edge research into diabetes (CIHR-INMD). 100 Years of Insulin: Accelerating Canadian Discoveries to Defeat Diabetes is a significant initiative that the Institute launched in 2019 to increase funding for Canadian researchers so they can work with collaborators to find novel approaches to preventing and treating diabetes and its complications. The region’s market growth is primarily influenced by powerful market rivals, increasing healthcare GDP spending, and improved government reimbursement for insulin treatment.

Competitive Landscape

The insulin resistance market is moderately competitive with local and global companies’ presence Glenmark Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Nova Nordisk, Teva Pharmaceuticals, Sanofi, GlaxoSmithKline, Mylan and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in October 2022, Glenmark Pharmaceuticals announced the introduction of Thiazolidinedione Lobeglitazone for the treatment of type 2 diabetes in adults. According to a statement from Glenmark Pharmaceuticals, there is a high frequency of insulin resistance among Indians, making LOBG an appealing treatment option for treating insulin-resistant diabetic patients with uncontrolled Type 2 diabetes

Glenmark Pharmaceuticals.

Overview: Glenmark Pharmaceuticals Ltd. (Glenmark) ‘s primary objective is developing novel chemical entities (NCEs). The company creates and sells both branded and generic formulations. Oncology, dermatology, and respiratory are just a few therapeutic specialties covered by the company’s formulations division. Additionally, it is used in numerous therapeutic contexts, including oral contraceptives, diabetes, and cardiovascular conditions. The firm produces and distributes active medicinal components (APIs). Glenmark has production sites in the Czech Republic, the United States, Argentina, and India.

Product Portfolio

LOBG: Thiazolidinedione Drug called lobeglitazone that increases insulin sensitivity The anti-diabetic drug will be offered for sale under the trade name LOBG . It has 0.5 mg of lobeglitazone and should be taken one daily as directed. LOBG is a desirable medical alternative for patients with Type 2 diabetes who are insulin resistant.

The global Insulin resistance market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.